The merger effectively ends Passage Bio as an independent entity. Current shareholders face massive dilution with only 7% pro forma ownership. The CVRs offer a speculative tailwind from legacy asset monetization but are highly uncertain. Monitor the shareholder vote and Nasdaq listing approval; if the deal closes, PASG will trade as a Remix Therapeutics entity with a new pipeline focus on REM-422.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 25 $4.33entry
- T+1 · 5mo ago +8.54%α +9.27% · $4.70
- T+5 · 5mo ago +5.77%α +4.21% · $4.58
- T+20 · 4mo ago +13.16%α +12.64% · $4.90
- T+60 · 8w ago +9.70%α +5.97% · $4.75
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Passage Bio entered into a definitive all-stock merger agreement with Remix Therapeutics, where pre-merger Passage shareholders will own only ~7% of the combined company. The deal is supported by an oversubscribed $100M+ PIPE led by Decheng Capital, funding the combined entity into 2028 to advance Remix's lead oral MYB mRNA degrader REM-422. Passage shareholders also receive contingent value rights tied to legacy gene therapy milestones, but the massive dilution and effective change of control make this a highly negative event for current PASG holders.
Key Financial Metrics
Key Facts
- Passage Bio shareholders will own approximately 7% of the combined company post-merger, with Remix shareholders (including PIPE investors) owning ~93%
- Concurrent PIPE of $69,999,999.28 plus convertible notes totaling at least $99,929,000 in gross proceeds
- Remix Equity Value set at $226M, Passage Equity Value at $20M in the merger exchange ratio
- Passage will change its name to Remix Therapeutics, Inc. and board/management will be replaced by Remix designees
- Contingent Value Rights (CVRs) issued to Passage shareholders for potential payments from legacy asset monetization (GM1 and MLD programs) through 2028
- Passage's existing gene therapy programs (PBFT02) are being wound down or divested as Legacy Assets
Financial Impact
Pre-merger Passage shareholders diluted to ~7% ownership of combined entity; combined company receives $100M+ in new capital; CVRs provide speculative upside from legacy asset payments (80% of GM1 payments and 100% of MLD payments, less deductions)
Risk Factors
- Deal may fail to close if Passage shareholders vote against the issuance or charter amendment
- CVR payments may be zero if Gemma does not make milestone payments or if Permitted Deductions consume proceeds
- Combined company's success depends entirely on Remix's unapproved drug REM-422, which carries clinical and regulatory risk
- Potential stockholder litigation challenging the merger terms
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-077306 |
| Document: tm2618476d1_ex10-6.htm | 0001104659-26-077306 |
| Document: tm2618476d1_ex10-4.htm | 0001104659-26-077306 |
Track record
15 reports on PASG
2 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +22.24% at T+60 after the May 27, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 6, 202610d ago 8-K Neutral 5/10 Entry $3.98 Now $4.13 +3.90% settles Dec 7
- Oct 13, 20265w ago EFFECT Neutral 3/10 Entry $3.64 to $3.78 Now $4.13 +13.46% ▲ +3.85% +7.46% vs SPY
- Oct 8, 20265w ago S-4/A Bearish 6/10 Entry $3.69 to $3.98 Now $4.13 −11.92% ▼ −7.72% −13.28% vs SPY
- Oct 5, 20266w ago S-4/A Neutral 5/10 Entry $4.08 to $3.41 Now $4.13 +1.23% ▼ −16.47% −13.56% vs SPY
- Sep 21, 20268w ago S-4/A Neutral 5/10 Entry $4.95 to $3.60 Now $4.13 −16.57% ▼ −27.27% −26.71% vs SPY
- Sep 2, 202610w ago S-4/A / 425 Bearish 8/10 Entry $4.75 to $4.12 Now $4.13 +13.05% ▲ +13.26% +12.08% vs SPY
- Sep 2, 202610w ago 8-K Bullish 8/10 Entry $4.75 to $4.12 Now $4.13 −13.05% ▼ −13.26% −12.08% vs SPY
- Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
- Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
- Jun 24, 202620w ago 8-K Bearish 7/10 Viewing Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers